Front Pharmacol ; Although the development of CRC was extensively studied, limited number of new therapies were developed in the last few years.
The aim of this study is to present our experience with using bevacizumab beyond disease progression at different dosage levels in mCRC patients, in terms of overall survival, progression-free survival, time to treatment failure, and toxicities. Methods: We performed heterogeneous prostate on ct scan consecutive retrospective analysis of patients with confirmed mCRC who were treated with bevacizumab at "Prof Dr. All patients had received bevacizumab beyond progression BYP which is defined as continuing bevacizumab administration through second-line treatment despite disease progression.
In each group, we evaluated the prognostic factors that influenced survival and treatment outcome.
Results: One hundred and fifty-one patients were included in the study. Themedian age of patients receiving double dose bevacizumab DDB and standard dose bevacizumab SDB was 58 years range and 57 years rangerespectively. Both oxaliplatin- and irinotecan-based regimens were found to be suitable partners for BYP.
Statistical analysis revealed that dose intensity, primary tumor location, and cumulative exposure to BYP had significant influence on survival.
Conclusion: Doubling the dose of bevacizumab after first progression may improve survival in mCRC patients. Increasing bevacizumab dose intensity could override the prognostic impact of primary tumor location in patients receiving double the dose of bevacizumab after first disease progression.